ストックスクリーナーアプリを入手
14.96
5.04%
-0.795
プレマーケット:
14.95
-0.015
-0.10%
Tandem Diabetes Care Inc (TNDM) 最新ニュース
TNDM stock down following Q1 earnings & revenue beat, gross margin up - MSN
Tandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed? - Yahoo Finance
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 5.1% Drop? GF Value Says Undervalued - GuruFocus
Tandem Diabetes Care (TNDM) chair emeritus reports new RSU grant and vesting - Stock Titan
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
Tandem Diabetes (TNDM) director reports 10,220 RSU grant and 8,759-share vesting - Stock Titan
Tandem Diabetes Care (TNDM) director receives 5,110 restricted stock units grant - Stock Titan
Tandem Diabetes (TNDM) director adds shares through RSU grant and vesting - Stock Titan
Director at Tandem Diabetes (NASDAQ: TNDM) adds RSUs and shares - Stock Titan
Tandem Diabetes (TNDM) director receives 10,220 RSU grant as prior award vests - Stock Titan
Tandem Diabetes (TNDM) director gets 10,220 RSUs as 8,759 vest - Stock Titan
Tandem Diabetes (TNDM) director Twomey reports RSU grant and 8,759-unit vesting - Stock Titan
Does Tandem Diabetes Care’s (TNDM) Expanded Incentive Plan Clarify Its Long‑Term Growth Priorities? - Sahm
Shareholders back charter changes and equity plan at Tandem Diabetes (NASDAQ: TNDM) - Stock Titan
Reasons to hold Tandem Diabetes stock in your portfolio for now - MSN
TNDM Technical Analysis | Trend, Signals & Chart Patterns | TANDEM DIABETES CARE INC (NASDAQ:TNDM) - ChartMill
Small-Cap Stocks to Avoid: Wyndham, KBR, and Tandem Diabetes Care AnalysisNews and Statistics - IndexBox
Tandem Diabetes’s SWOT analysis: stock faces competitive headwinds By Investing.com - Investing.com Nigeria
Tandem Diabetes’s SWOT analysis: stock faces competitive headwinds - Investing.com
Tandem Diabetes (NASDAQ: TNDM) Form 144: 266 RSUs slated for sale - Stock Titan
Tandem Diabetes Care Stock Down 23% But Insiders Still In US$84k Profit - 富途牛牛
Tandem Diabetes (TNDM) CTO reports RSU vesting, ESPP share purchase and tax withholding - Stock Titan
Tandem Diabetes (TNDM) EVP reports RSU exercises, tax share withholding and trust holdings - Stock Titan
Tandem Diabetes Care (TNDM) legal chief reports RSU vesting, tax withholding and ESPP purchase - Stock Titan
Tandem Diabetes (TNDM) COO logs RSU vesting, tax withholding and ESPP purchase - Stock Titan
Tandem Diabetes (TNDM) exec gains shares via RSU vesting and ESPP - Stock Titan
Tandem Diabetes Care (TNDM) CEO reports RSU vesting, ESPP buy and tax withholding - Stock Titan
Tandem Diabetes (TNDM) CFO exercises RSUs and ESPP, increases share holdings - Stock Titan
Tandem Diabetes (TNDM) EVP gets RSU shares while company withholds stock for taxes - Stock Titan
Silver Economy Investing: Why the Healthcare Giants Are in Focus - TradingView
TNDM Maintained by B of A Securities -- Price Target Lowered to $25 - GuruFocus
Tandem Diabetes Care Price Target Cut to $25.00/Share From $35.00 by B of A Securities - Moomoo
Tandem Diabetes’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
BofA Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Cuts Target Price to $25 - Moomoo
Tandem Diabetes Care, Inc. Stock 12‑Month Price Target Cut to $30.8, Implies 140% Upside - TradingView
(TNDM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tandem Diabetes Care (TNDM) loses 26.5% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Tandem Diabetes Care, Inc. Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing - Minichart
Tandem Diabetes Care to end employment of chief commercial officer By Investing.com - Investing.com Canada
Tandem Diabetes Care to end employment of chief commercial officer - Investing.com UK
Tandem Diabetes Care Announces Leadership Change, Strategy Unchanged - TipRanks
Tandem Diabetes Care IncMark Novara, evp and chief commercial officer, to be terminated without causeSEC filing - marketscreener.com
Mark Novara to Exit Tandem Diabetes Care as EVP & Chief Commercial Officer - TradingView
Tandem Diabetes (NASDAQ: TNDM) to terminate EVP & Chief Commercial Officer - Stock Titan
Tandem Diabetes Care, Inc. Announces Termination of Mark Novara as Executive Vice President and Chief Commercial Officer, Effective May 18, 2026 - marketscreener.com
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up - TradingView
Tandem Diabetes Care Q1 earnings call highlights - MSN
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold? - TradingView
Benchmark initiates coverage of Tandem Diabetes Care (TNDM) with hold recommendation - MSN
Transcript : Tandem Diabetes Care, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 02 - marketscreener.com
Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today - Yahoo Finance
TNDM Initiated Coverage by Benchmark -- Rating Set to Hold - GuruFocus
This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Benchmark initiates Tandem Diabetes stock with Hold on channel shift By Investing.com - Investing.com Canada
TNDM Q1 Deep Dive: Margin Expansion and Pipeline Advances Amid Business Model Shift - Yahoo Finance
0.22%
1.41%
大文字化:
|
ボリューム (24 時間):